PUBLIC COMPANY
save$TRVITrevi Therapeutics, Inc.
$TRVI18.25-2.98%New Haven, CT, USupdated 7h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
- phase1NAL ER IPF Respiratory Function and Safety Study
- phase2Refractory Chronic Cough Improvement Via NAL ER (RIVER)
- phase1A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
- phase1Study of Nalbuphine ER in Participants With Hepatic Impairment
- phase1A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
- phase2Cough Reduction in IPF With Nalbuphine ER
- phase3PRISM Study-Pruritus Relief Through Itch Scratch Modulation
🐶 Hiring Signal
News
- GSK shelves cough drug acquired in $2B dealMixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.biopharma_dive · 1mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that